Interleukin-33 (IL-33) is a IL-1 family member of cytokines exerting pleiotropic activities. In the steady-state, IL-33 is expressed in the nucleus of epithelial, endothelial, and fibroblast-like cells acting as a nuclear protein. In response to tissue damage, infections or necrosis IL-33 is released in the extracellular space, where it functions as an alarmin for the immune system. Its specific receptor ST2 is expressed by a variety of immune cell types, resulting in the stimulation of a wide range of immune reactions. Recent evidences suggest that different IL-33 isoforms exist, in virtue of proteolytic cleavage or alternative mRNA splicing, with potentially different biological activity and functions. Although initially studied in the context of allergy, infection, and inflammation, over the past decade IL-33 has gained much attention in cancer immunology. Increasing evidences indicate that IL-33 may have opposing functions, promoting, or dampening tumor immunity, depending on the tumor type, site of expression, and local concentration. In this review we will cover the biological functions of IL-33 on various immune cell subsets (e.g., T cells, NK, Treg cells, ILC2, eosinophils, neutrophils, basophils, mast cells, DCs, and macrophages) that affect anti-tumor immune responses in experimental and clinical cancers. We will also discuss the possible implications of diverse IL-33 mutations and isoforms in the anti-tumor activity of the cytokine and as possible clinical biomarkers.

The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity / Afferni, C.; Buccione, C.; Andreone, S.; Galdiero, M. R.; Varricchi, G.; Marone, G.; Mattei, F.; Schiavoni, G.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 9:NOV(2018). [10.3389/fimmu.2018.02601]

The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity

Andreone S.;
2018

Abstract

Interleukin-33 (IL-33) is a IL-1 family member of cytokines exerting pleiotropic activities. In the steady-state, IL-33 is expressed in the nucleus of epithelial, endothelial, and fibroblast-like cells acting as a nuclear protein. In response to tissue damage, infections or necrosis IL-33 is released in the extracellular space, where it functions as an alarmin for the immune system. Its specific receptor ST2 is expressed by a variety of immune cell types, resulting in the stimulation of a wide range of immune reactions. Recent evidences suggest that different IL-33 isoforms exist, in virtue of proteolytic cleavage or alternative mRNA splicing, with potentially different biological activity and functions. Although initially studied in the context of allergy, infection, and inflammation, over the past decade IL-33 has gained much attention in cancer immunology. Increasing evidences indicate that IL-33 may have opposing functions, promoting, or dampening tumor immunity, depending on the tumor type, site of expression, and local concentration. In this review we will cover the biological functions of IL-33 on various immune cell subsets (e.g., T cells, NK, Treg cells, ILC2, eosinophils, neutrophils, basophils, mast cells, DCs, and macrophages) that affect anti-tumor immune responses in experimental and clinical cancers. We will also discuss the possible implications of diverse IL-33 mutations and isoforms in the anti-tumor activity of the cytokine and as possible clinical biomarkers.
2018
cancer; IL-33; IL-33 isoforms; immune cell subsets; tumor immunology; animals; humans; immunity; immunomodulation; interleukin-33; neoplasms
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity / Afferni, C.; Buccione, C.; Andreone, S.; Galdiero, M. R.; Varricchi, G.; Marone, G.; Mattei, F.; Schiavoni, G.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 9:NOV(2018). [10.3389/fimmu.2018.02601]
File allegati a questo prodotto
File Dimensione Formato  
Afferni_Pleiotropic_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 3.12 MB
Formato Adobe PDF
3.12 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1342554
Citazioni
  • ???jsp.display-item.citation.pmc??? 50
  • Scopus 83
  • ???jsp.display-item.citation.isi??? 78
social impact